- Home
- IOVA vs LICN Comparison
IOVA vs LICN Comparison
Compare IOVA & LICN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- LICN
- Stock Information
- Founded
- IOVA 2007
- LICN 2004
- Country
- IOVA United States
- LICN China
- Employees
- IOVA N/A
- LICN N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- LICN
- Sector
- IOVA Health Care
- LICN
- Exchange
- IOVA Nasdaq
- LICN Nasdaq
- Market Cap
- IOVA 1.0B
- LICN 2.1M
- IPO Year
- IOVA N/A
- LICN 2023
- Fundamental
- Price
- IOVA $3.61
- LICN $3.68
- Analyst Decision
- IOVA Strong Buy
- LICN
- Analyst Count
- IOVA 9
- LICN 0
- Target Price
- IOVA $18.22
- LICN N/A
- AVG Volume (30 Days)
- IOVA 10.0M
- LICN 94.4K
- Earning Date
- IOVA 05-08-2025
- LICN 01-01-0001
- Dividend Yield
- IOVA N/A
- LICN N/A
- EPS Growth
- IOVA N/A
- LICN 36.90
- EPS
- IOVA N/A
- LICN 55.10
- Revenue
- IOVA $164,070,000.00
- LICN $41,929,000.00
- Revenue This Year
- IOVA $182.20
- LICN N/A
- Revenue Next Year
- IOVA $62.10
- LICN N/A
- P/E Ratio
- IOVA N/A
- LICN $0.07
- Revenue Growth
- IOVA 13698.99
- LICN 24.86
- 52 Week Low
- IOVA $2.70
- LICN $0.04
- 52 Week High
- IOVA $14.23
- LICN $7.55
- Technical
- Relative Strength Index (RSI)
- IOVA 54.38
- LICN 53.16
- Support Level
- IOVA $2.89
- LICN $2.60
- Resistance Level
- IOVA $3.43
- LICN $3.70
- Average True Range (ATR)
- IOVA 0.30
- LICN 0.55
- MACD
- IOVA 0.10
- LICN -0.01
- Stochastic Oscillator
- IOVA 95.60
- LICN 46.96
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
About LICN Lichen China Limited
Lichen International Ltd formerly Lichen China Ltd is a holding company. The company, along with its subsidiaries provides financial and taxation solution services; education support services; and software and maintenance services. The company generates Majority revenue from Financial and taxation solution services.